Lineage Cell Therapeutics (LCTX) Change in Acquisitions & Divestments (2023 - 2026)

Lineage Cell Therapeutics' Change in Acquisitions & Divestments history runs 4 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 198.25% year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $6.0 million (up 195.59% YoY), while the FY2025 annual figure was $2.0 million, up 11011.11% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $6.0 million, up from $2.0 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $24.3 million in Q2 2023, with the low at -$4.0 million in Q4 2024.
• The 4-year median for Change in Acquisitions & Divestments is $5.8 million (2023), against an average of $7.9 million.
• The sharpest annual moves came in 2024 and 2026: Change in Acquisitions & Divestments slumped 140.5% in 2024, then surged 198.25% in 2026.
• Lineage Cell Therapeutics' Change in Acquisitions & Divestments stood at $9.8 million in 2023, then plunged by 140.5% to -$4.0 million in 2024, then surged by 150.23% to $2.0 million in 2025, then soared by 198.25% to $6.0 million in 2026.
• Business Quant data shows LCTX's Change in Acquisitions & Divestments at $6.0 million in Q1 2026, $2.0 million in Q1 2025, and -$4.0 million in Q4 2024.